Life Science News

RSS

Thermo Fisher Scientific, Eli Lilly expand clinical trial materials supply chain relationship

Thermo Fisher Scientific Inc., the world leader in serving science, and biopharmaceutical company Eli Lilly and Company, announced today that they have expanded their clinical trial materials supply chain relationship. As part of a new five-year agreement, the Fisher Clinical Services business of Thermo Fisher will take over responsibility for Lilly’s in-house clinical trial materials manufacturing, packaging and labeling operations on-site at the Lilly Technology Center – North in Indianapolis. This transition is expected to be completed in the summer of 2010.

From Thermo Fisher Scientific Inc. 27 Mar 2010

Pressure BioSciences announces presentations on advantages of PCT

Pressure BioSciences, Inc. today announced that five presentations on the advantages of pressure cycling technology (PCT) in the preparation, processing, identification, and quantification of proteins were made at last week's annual meeting of US HUPO (Human Proteomics Organization) in Denver, Colorado.

From Thermo Fisher Scientific Inc. 19 Mar 2010

Malvern image analysis system measures sub-visible particulates in biotherapeutics

Specialists at Malvern Panalytical have demonstrated the application of dynamic particle image analysis to the measurement of sub-visible particulates in biological therapeutics, using the Sysmex FPIA-3000 particle characterization system.

From Malvern Panalytical 18 Mar 2010

Avid Bioservices highlights data of single-use bioreactors and traditional stainless steel bioreactors

Avid Bioservices, Inc. today presented data highlighting the comparability of production run performance between the company's single-use bioreactors (Thermo Scientific HyClone S.U.B.) and its traditional stainless steel bioreactors at the Thermo Scientific BioProduction Optimization Workshop in San Francisco, California.

From Thermo Fisher Scientific Inc. 17 Mar 2010

Roche Diagnostics named sole source supplier for Premier's blood glucose monitoring devices

Roche Diagnostics announced today that it has been awarded contracts for blood glucose monitoring and clinical chemistry/immunoassay lab analyzers from Premier Purchasing Partners, L.P., Inc., the group purchasing unit of Premier, Inc. Roche was also named the sole source supplier for blood glucose in Premier's exclusive ASCEND supply chain performance program.

From Roche Sequencing and Life Science 16 Mar 2010

Cytori Therapeutics reports total revenues of $14.7M for 2009

Cytori Therapeutics is reporting its financial results for the year ended December 31, 2009.

From Evident Corporation - Life Sciences 12 Mar 2010

Peregrine Pharmaceuticals' third-quarter fiscal 2010 total revenues up 45%

Peregrine Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing innovative monoclonal antibodies for the treatment of cancer and serious viral infections, today announced financial results for the third quarter of fiscal year (FY) 2010 ended January 31, 2010. The company also provided an update on its clinical programs and corporate developments.

From Thermo Fisher Scientific Inc. 11 Mar 2010

Thermo Fisher Scientific acquires Finnzymes

Thermo Fisher Scientific Inc., the world leader in serving science, has completed its previously announced acquisition of Finnzymes. The business is a well-recognized provider of integrated tools for high-performance polymerase chain reaction (PCR), including reagents, instruments, consumables and kits that make the PCR process faster and more accurate for applications including basic genomic research, genetic testing, forensics and food safety.

From Thermo Fisher Scientific Inc. 5 Mar 2010

Olympus America signs nonexclusive worldwide licensing agreement with Omnyx

Olympus America Inc. has signed a nonexclusive worldwide licensing agreement with Omnyx, LLC, a joint venture of GE Healthcare and the University of Pittsburgh Medical Center, allowing Omnyx to access an extensive portfolio of Olympus America patents in the field of virtual microscopy and digital pathology, to help develop solutions in the digital pathology field.

From Evident Corporation - Life Sciences 1 Mar 2010

CAMH signs licensing agreement with US-based Athena Diagnostics to market new genetic test

For the second time in as many months the Centre for Addiction and Mental Health has signed a licensing agreement with US-based Athena Diagnostics Inc. to market a new genetic test.

From Thermo Fisher Scientific Inc. 26 Feb 2010

Thermo Fisher Scientific completes previously announced acquisition of Ahura Scientific

Thermo Fisher Scientific Inc., the world leader in serving science, today announced that it has completed its previously announced acquisition of Ahura Scientific, a leader in handheld Raman and FT-IR (Fourier-transform infrared) spectroscopy instruments that are used worldwide in the identification of chemicals for safety, security and pharmaceutical applications.

From Thermo Fisher Scientific Inc. 26 Feb 2010

Unique technology identifies drug candidates, speeds up drug development

The search for new therapeutic agents is time-consuming and expensive. Pharmaceutical companies may have to screen thousands of compounds for the ability to bind a target molecule before they hit upon a promising drug candidate.

From NanoTemper Technologies 24 Feb 2010

Olympus launches new medical devices for LESS surgery

A variety of new medical devices specifically designed for Laparo-Endoscopic Single-Site surgery (LESS surgery) has been announced and introduced by Olympus Europa Holding GmbH and Olympus Medical Systems Corporation. LESS surgery is an advanced, minimally invasive operation technique by which an endoscope and hand instruments are inserted through an access port anchored in just one small incision, usually made in the navel. After developing all the medical devices needed to perform LESS surgery, Olympus has yet again proven its leadership in the field. The release of these innovative devices in Europe took place in autumn 2009.

From Evident Corporation - Life Sciences 18 Feb 2010

Morphologi G3 adds new dimension to Solvay Pharmaceuticals R&D

Solvay Pharmaceuticals Inc. (Marietta, GA, USA) was the first company in the United States to install the innovative Morphologi G3 image analysis-based particle characterization system from Malvern Panalytical.

From Malvern Panalytical 9 Feb 2010

Tecan Group, Enigma Diagnostics sign manufacturing and supply agreement for Enigma ML instruments

The Tecan Group, a leading global provider of laboratory instruments and solutions, and Enigma Diagnostics Limited, the decentralised and point-of-care molecular diagnostics company, announced today the signing of a manufacturing and supply agreement for Enigma's ML instruments.

From Tecan 5 Feb 2010

Thermo Fisher Scientific announces record $2.84 billion revenue in fourth-quarter 2009

Thermo Fisher Scientific Inc., the world leader in serving science, reported that revenues increased 7% to a record $2.84 billion in the fourth quarter of 2009, compared with $2.65 billion in the 2008 quarter. The revenue growth reflects the impact of currency translation, which increased revenues by 3%, and the effect of acquisitions, which also increased revenues by 3%.

From Thermo Fisher Scientific Inc. 3 Feb 2010

Fluxion Biosciences to defend against alleged automated patch clamp system patent infringement lawsuit

Fluxion Biosciences, Inc. announced today that a lawsuit alleging patent infringement had been filed against it in the US District Court of Northern California by Cellectricon AB, its competitor in the field of automated ion channel screening systems for drug discovery. Cellectricon has asserted U.S. Patents Nos. 7,390,650, 7,470,518, and 7,563,614 in the litigation, as well as U.S. Patent No. 5,376,252, which is owned by Gyros and licensed to Cellectricon.

From Fluxion Biosciences 3 Feb 2010

Cellectricon resumes litigation against Fluxion Biosciences over alleged patent infringement

Cellectricon AB today announced that it has resumed its litigation against Fluxion Biosciences, Inc. Cellectricon filed the lawsuit in July 2009 in the United States District Court for the Northern District of California alleging infringement of several United States patents issued or licensed to Cellectricon for microfluidic technology used in Cellectricon's state-of-the-art ion channel drug screening solution, the Dynaflow(R)HT System. Cellectricon's U.S. Patents Nos. 7,390,650, 7,470,518 and 7,563,614 have been asserted in the litigation, as well as U.S. Patent No. 5,376,252, which is owned by Gyros, and licensed to Cellectricon.

From Fluxion Biosciences 2 Feb 2010

Thermo Fisher Scientific to acquire Finnzymes

Thermo Fisher Scientific Inc., the world leader in serving science, announced today that it has signed a definitive agreement to acquire Finnzymes, a well-recognized provider of integrated tools for molecular biology analysis, including reagents, instruments, consumables and kits. Headquartered in Espoo, Finland, Finnzymes has 90 employees and generated revenue of $20 million in 2009.

From Thermo Fisher Scientific Inc. 2 Feb 2010

Thermo Fisher Scientific provides public notice to the holders Floating Rate Convertible Senior Debentures

As required under the indenture covering Apogent Technologies Inc. Floating Rate Convertible Senior Debentures due 2033 (CUSIP No. 03760AAK7), Thermo Fisher Scientific Inc. is providing public notice to the holders of these bonds that they have the right to receive contingent interest for the current quarterly interest period ending March 15, 2010.

From Thermo Fisher Scientific Inc. 30 Jan 2010